At present, the best therapeutic approach for melanoma patients consists in a combination of drugs that inhibits the kinase activity of BRAF (BRAFi) and MEK (MEKi), downstream effectors of the MAPK pathway; in addition, new treatments with immune checkpoint inhibitors are now being used for advanced or metastatic melanomas [19,93]. The gene discussed is BRAF; the disease is melanoma.